MPM BioImpact and Pfizer Ventures led a $80m Series A funding round in Crossbow Therapeutics.

MPM BioImpact, a biotechnology investment firm, and Pfizer Ventures, a company that invests in life therapeutics, platform technologies, diagnostics, drug delivery, pharmaceutical services, healthcare IT industries, and other life science, led a $80m Series A funding round in Crossbow Therapeutics, a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture Investment, and Mirae Asset Capital. “We aim to cure cancer. With unparalleled accuracy and potency, our revolutionary T-Bolt™ products strike cancer cells like a crossbow shoots bolts at its target. The influx of additional capital enables us to scale our efforts to build an arsenal of TCR-mimetic-based immunotherapies designed to overcome the limitations of current treatments,” Briggs Morrison, Crossbow Therapeutics CEO.